neurology

News

Closeup of X-ray photography of human brain

Study uncovers new Alzheimer's genes, links to immune disrup...

The largest-ever study of genetics in Alzheimer's disease patients has identified 42 new genes that appear to be linked to the neurodegenerative disorder.

News

Patients dismayed as FDA advisors narrowly reject Amylyx' AL...

By a narrow margin, an FDA advisory committee has voted against approval of Amylyx' experimental medicine for amyotrophic lateral sclerosis until the company can provide more evidence that

News

Biogen finally publishes its phase 3 Aduhelm data

After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to l

News

Eisai hands off responsibility for Aduhelm to Biogen

Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer's therapy Aduhelm, handing over full responsibility to its US counterpart.

News

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Roche starts new four-year trial of Alzheimer's drug gantene...

With prospects of an early, accelerated approval for Roche's Alzheimer's disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the hope of b

News

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront.

Study uncovers new Alzheimer's genes, links to immune disrup...

Patients dismayed as FDA advisors narrowly reject Amylyx' AL...

Biogen finally publishes its phase 3 Aduhelm data

Eisai hands off responsibility for Aduhelm to Biogen

Roche starts new four-year trial of Alzheimer's drug gantene...

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

ASH: AstraZeneca's dual-wielding CAR-T shows promise

How to meet your physicians where they are online

neurology

Editor's Picks